Developer docs
API playgroundTry for free, no card

Search company profiles

Parsemus Foundation

Full company profile

uuid002hds5

Namestring
Parsemus Foundation
Legal namestring
Parsemus Foundation
Websiteurl
parsemus.org
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nonprofit medical research, animal health research, neglected disease research, veterinary education resources, medical research funding
Industry1 code
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
Product category
Nonprofit Medical Research Foundation
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Foundation/Donor Funding
TypeLicensing Royalties
Description

As a private nonprofit operating foundation, Parsemus Foundation operates primarily through donations and grants. The foundation's website states they accept donations and their professional profile can be found on ProPublica (EIN: 203968895). The foundation supports clinical trials and research studies through funding.

parsemus.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Parsemus Foundation is a private nonprofit operating foundation that funds small-scale medical research studies in neglected areas of human and animal health and shares the results publicly to change treatment practice. Its portfolio includes research projects on male contraception (Vasalgel/Plan A), hormone-sparing pet sterilization, Alzheimer's prevention, menopause, metformin/COVID-19, and nonsurgical tumor treatments, complemented by free educational resources and a veterinarian directory. The foundation does not sell commercial products; it operates through donations, grants, and research partnerships with universities and companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 41-63% reduction in Long COVID incidence with metformin treatment started within 4-7 days of symptoms (COVID-OUT trial supported by Parsemus)
+2 more records
Product overview1 text field

The Parsemus Foundation is a private nonprofit operating foundation that creates meaningful improvements in human and pet health through advancing innovative and neglected medical research. Rather than a commercial product company, it operates as an educational and research funding organization. Its portfolio includes human health research projects (covering Alzheimer's, menopause, metformin, male contraception, COVID-19), pet health projects (hormone-sparing sterilization, nonsurgical treatments), a free Veterinarian Directory, and educational resources including the Hormonally platform for women's hormone health. The foundation funds small studies, shares results to change treatment practice, and advocates for evidence-based approaches to health.

Product and service6 records
1Vasalgel (Plan A Male Contraceptive)
CategoryContraceptive research project
Description

Non-hormonal, long-acting male contraceptive using a hydrogel delivery system. Originally developed by Parsemus Foundation and partnered with NEXT Life Sciences in 2022 to commercialize as Plan A as an affordable and accessible birth control option for men.

2Hormone-Sparing Sterilization Research Projects
CategoryPet health research project
Description

Research projects exploring alternatives to traditional spay/neuter in dogs and cats, designed to support lifelong well-being while still preventing reproduction. Includes studies on hormone-sparing procedures, identification of sterilized dogs, and health outcome comparisons.

3Veterinarian Directory
CategoryService
Description

Free searchable directory for pet owners to locate veterinarians offering hormone-sparing spay/neuter, hormone restoration, or nonsurgical treatments, filterable by location and service type.

4Hormonally Platform
CategoryEducational platform
Description

Nonprofit platform providing expert-backed insights, interactive tools, community support, and the latest research updates on women's hormonal conditions and treatments.

5Injectable Cat Contraceptive (Gene Therapy)
CategoryPet health research project
Description

Single-shot gene therapy contraceptive for female cats using a harmless virus to deliver an anti-Müllerian hormone (AMH) gene, preventing ovulation for at least two years and potentially a lifetime.

6Metformin Long COVID Prevention Research
CategoryHuman health research project
Description

Funded clinical trial research on metformin (and ivermectin/fluvoxamine) for COVID-19 and Long COVID prevention, including enrollment support and bilingual outreach, demonstrating a 41-63% reduction in Long COVID incidence with early metformin treatment.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Parsemus Foundation initially developed Vasalgel (a non-hormonal, long-acting male contraceptive using a hydrogel) and partnered with NEXT Life Sciences in 2022 to bring the product to market as Plan A, an affordable and accessible birth control option for men. NEXT Life Sciences completed a successful clinical trial of the delivery system in Canada involving 50 men under FDA-compliant standards.

2Hormonally
Strategic tierMinorTypeOthers
Description

Hormonally is a project of the Parsemus Foundation dedicated to promoting equal access to evidence-based information on women's hormone health. The Parsemus Foundation provided support to start this initiative. Lauren Redfern, Ph.D. serves as Executive Director of Hormonally.

parsemus.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parsemus Foundation supported the COVID-OUT clinical trial conducted by the University of Minnesota, which studied the effectiveness of metformin, ivermectin, and fluvoxamine in preventing Long COVID. The foundation provided enrollment support and bilingual outreach for the trial. Results showed metformin reduced Long COVID by 41-63%.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on canine health outcomes study distributed mainly by Good Dog, which involved owner surveys for over 6,000 dogs comparing health outcomes for hormone-sparing sterilization procedures with sexually intact dogs or traditionally spayed/neutered dogs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Parsemus Foundation provided funding for a study conducted by researchers at the University of Saskatchewan using lithium orotate in a mouse model of Alzheimer's disease, supporting research on lithium for Alzheimer's disease prevention.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

A large private foundation that funds medical research and clinical care improvement. Comparable as a private operating foundation funding innovative health research, though at a substantially larger scale and with a broader portfolio than Parsemus.

TypeDirect peer
Description

A nonprofit that funds canine health research with a focus on breed-specific disease and welfare. Overlaps with Parsemus's dog-health research on spay/neuter outcomes, hormone restoration, and prostate issues, and serves a similar veterinary and dog-owner audience.

TypeDirect peer
Description

One of the largest nonprofit foundations funding animal health research, supporting studies across species including dogs and cats. Directly comparable in mission to Parsemus's pet health portfolio (hormone-sparing sterilization, enlarged prostate, hormone restoration) but at a much larger scale.

TypeBroad incumbent
Description

The largest U.S. philanthropy devoted to health, funding research and policy across public health topics. Comparable as a major private foundation advancing health research and practice change, but with a much larger endowment and institutional footprint than Parsemus.

TypeEmerging player
Description

A for-profit company that took over development of Vasalgel as Plan A and completed its first FDA-compliant clinical trial. Not a peer in mission or structure, but the entity through which Parsemus's flagship research reaches commercialization, making it the most directly linked adjacent organization.

TypeBroad incumbent
Description

A global nonprofit research organization conducting biomedical and social science research on reproductive health, HIV, and gender equity. Much larger and broader than Parsemus but operates at the intersection of nonprofit research funding and reproductive health innovation, where Parsemus's Vasalgel/Plan A work also sits.

TypeDirect peer
Description

A family foundation dedicated to revolutionizing the status and well-being of companion animals, including funding research on animal welfare and population health. Comparable to Parsemus's mission of advancing humane, evidence-based care for pets, particularly in sterilization and shelter medicine.

TypeBroad incumbent
Description

The world's largest private foundation, with major global health and reproductive health funding programs. Conceptually similar to Parsemus in backing medical research that commercial players underserve, but operates at vastly greater scale and geographic scope.

TypeDirect peer
Description

A global nonprofit R&D organization that develops treatments for diseases neglected by commercial pharma. Shares Parsemus's explicit thesis that medical areas with low profit potential require dedicated nonprofit funding, and follows a similar model of funding small studies to de-risk innovation.

10Male Contraceptive Initiative
TypeDirect peer
Description

A small U.S. nonprofit that exclusively funds research and development of new male contraceptive methods. Almost identical organizational model to Parsemus: small team, donor-funded, focused on a single neglected reproductive health area, and working to de-risk early-stage science for eventual commercial handoff.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Parsemus Foundation

Nonprofit Medical Research Foundationparsemus.org

Parsemus Foundation firmographics

Firmographics
Name
Parsemus Foundation
Legal name
Parsemus Foundation
Website
https://parsemus.org
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Parsemus Foundation industry classification

Industry
Product category
Nonprofit Medical Research Foundation
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Nonprofit medical research
  • Animal health research
  • Neglected disease research
  • Veterinary education resources
  • Medical research funding

Where Parsemus Foundation is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Parsemus Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Foundation/Donor Funding: As a private nonprofit operating foundation, Parsemus Foundation operates primarily through donations and grants. The foundation's website states they accept donations and their professional profile can be found on ProPublica (EIN: 203968895). The foundation supports clinical trials and research studies through funding.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Parsemus Foundation product offering

Product offering

Core offering

Parsemus Foundation is a private nonprofit operating foundation that funds small-scale medical research studies in neglected areas of human and animal health and shares the results publicly to change treatment practice. Its portfolio includes research projects on male contraception (Vasalgel/Plan A), hormone-sparing pet sterilization, Alzheimer's prevention, menopause, metformin/COVID-19, and nonsurgical tumor treatments, complemented by free educational resources and a veterinarian directory. The foundation does not sell commercial products; it operates through donations, grants, and research partnerships with universities and companies.

Product overview

The Parsemus Foundation is a private nonprofit operating foundation that creates meaningful improvements in human and pet health through advancing innovative and neglected medical research. Rather than a commercial product company, it operates as an educational and research funding organization. Its portfolio includes human health research projects (covering Alzheimer's, menopause, metformin, male contraception, COVID-19), pet health projects (hormone-sparing sterilization, nonsurgical treatments), a free Veterinarian Directory, and educational resources including the Hormonally platform for women's hormone health. The foundation funds small studies, shares results to change treatment practice, and advocates for evidence-based approaches to health.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vasalgel (Plan A Male Contraceptive) Non-hormonal, long-acting male contraceptive using a hydrogel delivery system. Originally developed by Parsemus Foundation and partnered with NEXT Life Sciences in 2022 to commercialize as Plan A as an affordable and accessible birth control option for men.
  • Hormone-Sparing Sterilization Research Projects Research projects exploring alternatives to traditional spay/neuter in dogs and cats, designed to support lifelong well-being while still preventing reproduction. Includes studies on hormone-sparing procedures, identification of sterilized dogs, and health outcome comparisons.
  • Veterinarian Directory Free searchable directory for pet owners to locate veterinarians offering hormone-sparing spay/neuter, hormone restoration, or nonsurgical treatments, filterable by location and service type.
  • Hormonally Platform Nonprofit platform providing expert-backed insights, interactive tools, community support, and the latest research updates on women's hormonal conditions and treatments.
  • Injectable Cat Contraceptive (Gene Therapy) Single-shot gene therapy contraceptive for female cats using a harmless virus to deliver an anti-Müllerian hormone (AMH) gene, preventing ovulation for at least two years and potentially a lifetime.
  • Metformin Long COVID Prevention Research Funded clinical trial research on metformin (and ivermectin/fluvoxamine) for COVID-19 and Long COVID prevention, including enrollment support and bilingual outreach, demonstrating a 41-63% reduction in Long COVID incidence with early metformin treatment.

Quantifiable outcome

  • 41-63% reduction in Long COVID incidence with metformin treatment started within 4-7 days of symptoms (COVID-OUT trial supported by Parsemus)
  • +2 more outcomes

Companies that use Parsemus Foundation

Customer profile

Segments3 records

Ideal customer profiles3 records

Parsemus Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Parsemus Foundation partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • NEXT Life SciencescoreStrategic or Co-development Partner · 1 January 2022Parsemus Foundation initially developed Vasalgel (a non-hormonal, long-acting male contraceptive using a hydrogel) and partnered with NEXT Life Sciences in 2022 to bring the product to market as Plan A, an affordable and accessible birth control option for men. NEXT Life Sciences completed a successful clinical trial of the delivery system in Canada involving 50 men under FDA-compliant standards.
  • HormonallyminorOthersHormonally is a project of the Parsemus Foundation dedicated to promoting equal access to evidence-based information on women's hormone health. The Parsemus Foundation provided support to start this initiative. Lauren Redfern, Ph.D. serves as Executive Director of Hormonally.
  • University of Minnesota (COVID-OUT Trial)coreStrategic or Co-development PartnerParsemus Foundation supported the COVID-OUT clinical trial conducted by the University of Minnesota, which studied the effectiveness of metformin, ivermectin, and fluvoxamine in preventing Long COVID. The foundation provided enrollment support and bilingual outreach for the trial. Results showed metformin reduced Long COVID by 41-63%.
  • Good DogminorStrategic or Co-development PartnerResearch collaboration on canine health outcomes study distributed mainly by Good Dog, which involved owner surveys for over 6,000 dogs comparing health outcomes for hormone-sparing sterilization procedures with sexually intact dogs or traditionally spayed/neutered dogs.
  • University of SaskatchewanminorStrategic or Co-development PartnerParsemus Foundation provided funding for a study conducted by researchers at the University of Saskatchewan using lithium orotate in a mouse model of Alzheimer's disease, supporting research on lithium for Alzheimer's disease prevention.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Parsemus Foundation competitors and assessment

Company assessment

Broad incumbents

  • Doris Duke Charitable Foundation: A large private foundation that funds medical research and clinical care improvement. Comparable as a private operating foundation funding innovative health research, though at a substantially larger scale and with a broader portfolio than Parsemus.
  • Robert Wood Johnson Foundation: The largest U.S. philanthropy devoted to health, funding research and policy across public health topics. Comparable as a major private foundation advancing health research and practice change, but with a much larger endowment and institutional footprint than Parsemus.
  • Population Council: A global nonprofit research organization conducting biomedical and social science research on reproductive health, HIV, and gender equity. Much larger and broader than Parsemus but operates at the intersection of nonprofit research funding and reproductive health innovation, where Parsemus's Vasalgel/Plan A work also sits.
  • Bill & Melinda Gates Foundation: The world's largest private foundation, with major global health and reproductive health funding programs. Conceptually similar to Parsemus in backing medical research that commercial players underserve, but operates at vastly greater scale and geographic scope.

Direct peers

  • AKC Canine Health Foundation: A nonprofit that funds canine health research with a focus on breed-specific disease and welfare. Overlaps with Parsemus's dog-health research on spay/neuter outcomes, hormone restoration, and prostate issues, and serves a similar veterinary and dog-owner audience.
  • Morris Animal Foundation: One of the largest nonprofit foundations funding animal health research, supporting studies across species including dogs and cats. Directly comparable in mission to Parsemus's pet health portfolio (hormone-sparing sterilization, enlarged prostate, hormone restoration) but at a much larger scale.
  • Maddie's Fund: A family foundation dedicated to revolutionizing the status and well-being of companion animals, including funding research on animal welfare and population health. Comparable to Parsemus's mission of advancing humane, evidence-based care for pets, particularly in sterilization and shelter medicine.
  • Drugs for Neglected Diseases initiative: A global nonprofit R&D organization that develops treatments for diseases neglected by commercial pharma. Shares Parsemus's explicit thesis that medical areas with low profit potential require dedicated nonprofit funding, and follows a similar model of funding small studies to de-risk innovation.
  • Male Contraceptive Initiative: A small U.S. nonprofit that exclusively funds research and development of new male contraceptive methods. Almost identical organizational model to Parsemus: small team, donor-funded, focused on a single neglected reproductive health area, and working to de-risk early-stage science for eventual commercial handoff.

Emerging players

  • NEXT Life Sciences: A for-profit company that took over development of Vasalgel as Plan A and completed its first FDA-compliant clinical trial. Not a peer in mission or structure, but the entity through which Parsemus's flagship research reaches commercialization, making it the most directly linked adjacent organization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Parsemus Foundation social profiles

Digital presence

Parsemus Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Parsemus Foundation leadership team

Management profile

Number of profiles

Profiles4 records

Parsemus Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Parsemus Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parsemus Foundation

What does Parsemus Foundation do?

Parsemus Foundation is a private nonprofit operating foundation that funds small-scale medical research studies in neglected areas of human and animal health and shares the results publicly to change treatment practice. Its portfolio includes research projects on male contraception (Vasalgel/Plan A), hormone-sparing pet sterilization, Alzheimer's prevention, menopause, metformin/COVID-19, and nonsurgical tumor treatments, complemented by free educational resources and a veterinarian directory. The foundation does not sell commercial products; it operates through donations, grants, and research partnerships with universities and companies.

Is Parsemus Foundation a public or private company?

Parsemus Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Parsemus Foundation founded?

Parsemus Foundation was founded in 2008. It employs 1 to 10 people.

Where is Parsemus Foundation based?

Parsemus Foundation is headquartered in San Francisco, United States, in the North America region.

How does Parsemus Foundation make money?

One revenue line is on record: foundation/Donor Funding.

Who are Parsemus Foundation's main competitors?

Broad incumbents on record are Doris Duke Charitable Foundation, Robert Wood Johnson Foundation, Population Council and Bill & Melinda Gates Foundation. Direct peers are AKC Canine Health Foundation, Morris Animal Foundation, Maddie's Fund, Drugs for Neglected Diseases initiative and Male Contraceptive Initiative. NEXT Life Sciences is listed as an emerging player.

Does Parsemus Foundation have an API?

No public API is recorded for Parsemus Foundation.

What industry is Parsemus Foundation in?

Parsemus Foundation's product category is Nonprofit Medical Research Foundation. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ParsemusMale Contraceptive ResearchThe Parsemus Foundation has partnered with NEXT Life Sciences to advance the development of Vasalgel, a reversible non-hormonal male contraceptive. NEXT Life Sciences announced the launch of Plan A, utilizing this technology, with expectations for public availability by 2026. This collaboration marks the transition of Vasalgel from foundation-led research to commercial development.ParsemusAnother milestone for Plan A male contraceptiveNEXT Life Sciences has completed a successful clinical trial of the delivery system for Plan A, a non-hormonal, long-acting male contraceptive using a hydrogel called Vasalgel. The trial in Canada involved 50 men and confirmed the proprietary delivery method works under FDA-compliant standards across two continents, after prior testing in Australia. The Parsemus Foundation initially developed Vasalgel and partnered with NEXT Life Sciences in 2022 to bring the product to market as an affordable and accessible birth control option for men.ParsemusMale Contraceptive Initiative: History and accomplishmentsThe Male Contraceptive Initiative (MCI) celebrates its 10-year anniversary as a U.S.-based nonprofit and leading funder of male contraception research and advocacy. MCI traces its origins to the Parsemus Foundation, which first funded its formation in 2013, and has since expanded through research grants, public education programs, and its for-profit subsidiary the Contraceptive Accelerator Network (CAN). The organization focuses on advancing non-hormonal, reversible male contraceptive development and provides resources including fellowships, a youth advisory board, and an undergraduate grants program.PR NewswireTratar COVID com metformina reduz taxas de COVID longaA study published in The Lancet Infectious Diseases and supported by the Parsemus Foundation found that metformin reduced long COVID rates by 41% among patients who used it at the time of COVID-19 infection, with a 42% reduction in emergency room visits, hospitalizations, or death. The COVID-OUT clinical trial, a randomized quadruple-blind placebo-controlled study conducted by researchers from the University of Minnesota, also confirmed a 3.6-fold decrease in SARS-CoV-2 viral load among participants treated with metformin. Researchers are calling on the US and other nations to update their treatment guidelines to include metformin as an accessible option for COVID-19 patients.PR NewswireTreating COVID with Metformin Reduces Long COVID RatesA study published in The Lancet Infectious Diseases found that using metformin during COVID-19 infection reduces Long COVID rates by 41% and severe outcomes by 42%. Supported by the Parsemus Foundation, the trial involved researchers from multiple academic institutions testing generic medications against a placebo. The findings suggest metformin could serve as an accessible, low-cost preventive measure with significant public health implications.ParsemusPlan A™ male contraceptive to use Vasalgel technologyNEXT Life Sciences announced on March 22, 2023, its plan to develop a male contraceptive named Plan A™ utilizing Vasalgel technology. The company is collaborating with the Parsemus Foundation and Revolution Contraceptives LLC, who developed the underlying polymer hydrogel, to create a safe and reversible birth control solution. NEXT anticipates that Plan A will be available to consumers as early as 2026.ObserverA Birth Control Injection for Men Might Soon Be HereThe Parsemus Foundation is developing Vasalgel, a male contraceptive injection that blocks sperm in the vas deferens. It is currently tested on baboons, with no pregnancies in six months, and the nonprofit expects human trials next year and market launch in 2016-2017.United Press InternationalMale birth control shows promise in baboon studyVasalgel, a polymer injected into the vas deferens, proved effective in a baboon trial with no pregnancies after six months. The Parsemus Foundation plans human testing next year, aiming for a market launch by 2017. The treatment could shift birth control responsibility to men and reduce unwanted pregnancies.